Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1971 Apr;41(4):592–599. doi: 10.1111/j.1476-5381.1971.tb07067.x

Cardiovascular actions of substituted adenosine analogues

J A Angus, L B Cobbin, Rosemarie Einstein, M H Maguire
PMCID: PMC1702762  PMID: 5579459

Abstract

1. The effects of adenosine on systemic blood pressure, coronary blood flow and cardiac contractility and rate were studied in anaesthetized open-thorax dogs.

2. The potency and duration of action of substituted adenosine analogues were compared with that of adenosine.

3. With the exception of 2-chloroadenosine, in which coronary dilator activity was enhanced, substitution in the 2-position of the adenosine molecule reduced activity.

4. In all cases 2-substitution prolonged the duration of the coronary dilator activity of adenosine.

5. N6-Methylation of adenosine and 2-chloroadenosine reduced their coronary dilator activities, but had no effect on the duration of the response.

6. Comparison of the coronary dilator potencies and hypotensive activities of 2-ethylaminoadenosine and 2-methoxyadenosine indicates that these analogues have some specificity for the coronary bed.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BUNAG R. D., DOUGLAS C. R., IMAI S., BERNE R. M. INFLUENCE OF A PYRIMIDOPYRIMIDINE DERIVATIVE ON DEAMINATION OF ADENOSINE BY BLOOD. Circ Res. 1964 Jul;15:83–88. doi: 10.1161/01.res.15.1.83. [DOI] [PubMed] [Google Scholar]
  2. Baer H. P., Drummond G. I., Duncan E. L. Formation and deamination of adenosine by cardiac muscle enzymes. Mol Pharmacol. 1966 Jan;2(1):67–76. [PubMed] [Google Scholar]
  3. CLARKE D. A., DAVOLL J., PHILIPS F. S., BROWN G. B. Enzymatic deamination and vasodepressor effects of adenosine analogs. J Pharmacol Exp Ther. 1952 Nov;106(3):291–302. [PubMed] [Google Scholar]
  4. Drury A. N., Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol. 1929 Nov 25;68(3):213–237. doi: 10.1113/jphysiol.1929.sp002608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gerlach E., Deuticke B., Koss F. W. Einfluss von Pyrimidopyrimidin- und Pteridin-Derivaten auf Phosphat- und Adenosin-Permeabilität menschlicher Erythrocyten. Arzneimittelforschung. 1965 May;15(5):558–563. [PubMed] [Google Scholar]
  6. Juhran W., Kietmann K. Zur Regelung der Coronardurchblutung im akuten Sauerstoffmangel. Pflugers Arch. 1970;315(2):105–109. doi: 10.1007/BF00586654. [DOI] [PubMed] [Google Scholar]
  7. KOSS F. W., BEISENHERZ G., MAERKISCH R. [The elimination of adenosine from the blood under the influence of 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido-(5,4-d) pyrimidine and papaverine]. Arzneimittelforschung. 1962 Nov;12:1130–1131. [PubMed] [Google Scholar]
  8. Kolassa N., Pfleger K., Rummel W. Specificity of adenosine uptake into the heart and inhibition by dipyridamole. Eur J Pharmacol. 1970 Mar;9(3):265–268. doi: 10.1016/0014-2999(70)90221-9. [DOI] [PubMed] [Google Scholar]
  9. Kraupp O. Zum Wirkungsmechanismus der Coronardilatatoren. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1969;263(1):144–155. [PubMed] [Google Scholar]
  10. Pfleger K., Seifen E., Schöndorf H. Potenzierung der Adenosinwirkung am Herzen durch Inosin. Biochem Pharmacol. 1969 Jan;18(1):43–51. doi: 10.1016/0006-2952(69)90007-0. [DOI] [PubMed] [Google Scholar]
  11. ROWE G. G., AFONSO S., GURTNER H. P., CHELIUS C. J., LOWE W. C., CASTILLO C. A., CRUMPTON C. W. The systemic and coronary hemodynamic effects of adenosine triphosphate and adenosine. Am Heart J. 1962 Aug;64:228–234. doi: 10.1016/0002-8703(62)90334-4. [DOI] [PubMed] [Google Scholar]
  12. Raberger G., Kraupp O., Stühlinger W., Nell G., Chirikdjian J. J. The effects of an intracoronary infusion of adenosine on cardiac performance, blood supply and on myocardial metabolism in dogs. Pflugers Arch. 1970;317(1):20–34. doi: 10.1007/BF00586697. [DOI] [PubMed] [Google Scholar]
  13. Rockwell M., Maguire M. H. Studies on adenosine deaminase. I. Purification and properties of ox heart adenosine deaminase. Mol Pharmacol. 1966 Nov;2(6):574–584. [PubMed] [Google Scholar]
  14. Rubio R., Berne R. M., Katori M. Release of adenosine in reactive hyperemia of the dog heart. Am J Physiol. 1969 Jan;216(1):56–62. doi: 10.1152/ajplegacy.1969.216.1.56. [DOI] [PubMed] [Google Scholar]
  15. Rubio R., Berne R. M. Release of adenosine by the normal myocardium in dogs and its relationship to the regulation of coronary resistance. Circ Res. 1969 Oct;25(4):407–415. doi: 10.1161/01.res.25.4.407. [DOI] [PubMed] [Google Scholar]
  16. Schöndorf H., Rummel W., Pfleger K. Dosis-Wirkungs-Beziehungen zwischen Koronardurchfluss und Herzfrequenz für Adenosin. Experientia. 1969 Jan 15;25(1):44–45. doi: 10.1007/BF01903884. [DOI] [PubMed] [Google Scholar]
  17. Stafford A. Potentiation of adenosine and the adenine nucleotides by dipyridamole. Br J Pharmacol Chemother. 1966 Nov;28(2):218–227. doi: 10.1111/j.1476-5381.1966.tb01888.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. THORP R. H., COBBIN L. B. A study of the cardiovascular actions of 2-chloroadenosine. Arch Int Pharmacodyn Ther. 1959 Jan 1;118(1-2):95–106. [PubMed] [Google Scholar]
  19. WINBURY M. M., PAPIERSKI D. H., HEMMER M. L., HAMBOURGER W. E. Coronary dilator action of the adenine-ATP series. J Pharmacol Exp Ther. 1953 Nov;109(3):255–260. [PubMed] [Google Scholar]
  20. WOLF M. M., BERNE R. M. Coronary vasodilator properties of purine and pyrimidine derivatives. Circ Res. 1956 May;4(3):343–348. doi: 10.1161/01.res.4.3.343. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES